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Abstract
Themajority of studies on cranial cruciate ligament (CrCL) disease to date have been carried out on dogs that already sustained a
CrCL rupture, which is the end-stage of the disease. Investigations have recently been carried out to study humoral and cellular
immunopathological mechanisms in predisposed dogs before clinical rupture of the contralateral CrCL. The cruciate ligaments are
mainly composed of collagen type I, and immune responses to collagen have been suggested as a cause of CrCL degradation in
dogs. None of these investigations showed evidence that anticollagen type I antibodies alone initiate CrCL damage. However, in
predisposed dogs a distinct anticollagen type I antibody gradient was found towards the contralateral stifle joint that eventually
sustained a CrCL rupture, suggesting that there was an inflammatory process present in these joints before detectable joint
instability occurred. The importance of cellular reactivity to collagen type I in cruciate disease also remains unclear. Peripheral
blood mononuclear cell proliferation to collagen type I was very diverse in dogs with cruciate disease whereas some sham operated
dogs and healthy dogs tested positive as well. It is not yet determined whether cellular reactivity to collagen type I exists locally in
the stifle joints nor whether this could initiate CrCL degradation.
Inflammatory processes within the stifle joint can alter the composition of the cruciate ligaments. In animal models of immune-
mediated synovitis, the mechanical strength of the CrCL is significantly reduced. Immunohistochemical studies on synovial tissues
from dogs with rheumatoid arthritis and dogs with cruciate disease revealed that the pathologic features are similar in both joint
pathologies and that the differences are mainly quantitative. Joint inflammation induced by biochemical factors such as cytokines
has been implied in CrCL degeneration. In several studies, the levels of pro-inflammatory and T helper cytokines were measured in
dogs that sustained a CrCL rupture, but the exact role of the various cytokines in the pathogenesis of CrCL disease remains
inconclusive. More recently, the levels of the cytokines have been investigated over time in predisposed dogs before and after CrCL
rupture. IL-8 expression tended to be higher in stifle joints that will rupture their CrCL during the next 6 months than in those that
will not, indicating an inflammatory process in these joints before clinical rupture.
www.elsevier.com/locate/vetimm
Available online at www.sciencedirect.com
Veterinary Immunology and Immunopathology 125 (2008) 143–161Abbreviations: ACL, anterior cruciate ligament; bFGF, basic fibroblast growth factor; CD, cluster of differentiation; CIA, collagen-induced
arthritis; CrCL, cranial cruciate ligament; CRA, canine rheumatoid arthritis; IFN, interferon; IGF, insuline-like growth factor; IGFBP, insulin-like
growth factor binding protein; IL, interleukin; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; OA, osteoarthritis; PDGF,
platelet-derived growth factor; RA, rheumatoid arthritis; SF, synovial fluid; TGF, transforming growth factor; Th, T helper; TIMP, tissue inhibitor of
metalloproteinase; TNF, tumor necrosing factor; TRAP, tartrate-resistant acid phosphatase.
* Corresponding author. Tel.: +32 9 264 77 00.
E-mail address: marjandoom@hotmail.com (M. Doom).
0165-2427/$ – see front matter # 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.vetimm.2008.05.023
M. Doom et al. / Veterinary Immunology and Immunopathology 125 (2008) 143–161144This review provides a comprehensive overview of all possible implications of humoral and cell-mediated immune responses
published in dogs with cruciate disease together with publications from human joint diseases. Furthermore, this review highlights
recent findings on cytokines and proteinases in the accompanying joint inflammation.
# 2008 Elsevier B.V. All rights reserved.
Keywords: Antibodies; Cranial cruciate ligament; Cytokines; Dog; Osteoarthritis; Matrix metalloproteinase1. Introduction
Rupture of the cranial cruciate ligament (CrCL) is
one of the most important causes of hindlimb lameness
in dogs. While acute ligament injury may occur because
of a single event overload from trauma, the majority of
dogs rupture their CrCL during normal daily activities
due to secondary progressive and irreversible degen-
erative changes within the ligament itself (Zahm, 1965;
Pond and Campbell, 1972; Arnoczky and Marshall,
1981;Moore and Read, 1996; Narama et al., 1996). This
form of nontraumatic rupture is clinically termed
spontaneous CrCL rupture. In addition one third of the
cruciate patients rupture their contralateral CrCL within
8 months after rupture of the CrCL in the initially
affected stifle joint (Strande, 1967; Pond and Campbell,
1972; Bennett et al., 1988; Doverspike et al., 1993).
Partial or complete rupture of the CrCL results in stifle
joint instability and contributes significantly to the
development of osteoarthritis (OA) (Tirgari, 1977;
Elkins et al., 1991). OA is a highly prevalent
degenerative joint disorder in both animals and humans.
It is a progressive disease that is associated with pain,
stiffness and decreased range of movement. There are
no consistently effective methods for preventing the
development of CrCL degeneration or slowing its
progression. The etiopathogenesis of CrCL disease in
dogs remains unsolved in the majority of cases although
a great deal of attention has already been concentrated
on trying to identify factors that might lead to the
structural failure of the ligament. Rupture of the CrCL
has been associated with age-related ligament deterior-
aton (Vasseur et al., 1985), ligament deterioration due to
lack of exercise (Tipton et al., 1970), plasmocytic
lymphocytic synovitis (Hopper, 1993), and conforma-
tion abnormalities (Read and Robins, 1982; Slocum and
Slocum, 1993). Many of these suggested mechanisms
are still believed to be relevant in spontaneous CrCL
rupture, but none of them alone satisfactorily explains
the etiopathogenesis of this disease. Multiple factors
may lead to rupture of the CrCL and the subsequent
development of osteoarthritis (OA). A better knowledge
of the disease mechanisms in canine CrCL rupture
would enable us to accurately alter the degenerativeprocesses. May be, prophylactic measures could be
taken in the future. Humoral as well as cell-mediated
immune responses are illustrated in canine cruciate
disease. Nevertheless, there is increasing evidence that
joint inflammation precedes CrCL clinical rupture in
dogs with cruciate disease.
2. Humoral immunity in cruciate disease
The cruciate ligaments are covered by a fold of
synovial membrane and, although they have an intra-
articular position, they are in fact extra-synovial (Alm
and Stro¨mberg, 1974; Arnoczky et al., 1979). Due to the
protective synovial layer, the cruciate ligaments are
secluded from immune surveillance, and for this reason
they can act as self-antigens for autoantigenicity in
cases of damage (Osborne et al., 1995; Kobayashi et al.,
2006). One of the major components of joint tissue is
collagen. The cruciate ligaments and menisci are
mainly composed of collagen type I whereas the
articular cartilage is mainly composed of collagen type
II (van Sickle et al., 1993). Upon damage of these
structures, antigen is released in the SF, capable of
evoking an immune response (Fig. 1). Joint aspirates
from human patients with arthritis often contain wear
particles, for example, collagen, proteoglycan, bone,
uric acid, fibronectin, crystals and other, as yet
unidentified, materials (Evans et al., 1984; Xie et al.,
1992; Lohmander et al., 1993, 1994; Manicourt et al.,
2000; Nalbant et al., 2003). Some of these wear
particles have also been identified in the SF of dogs with
arthropathy (Arican et al., 1994; Innes et al., 1998; Chu
et al., 2002). The significance of these particles as
initiators, promoters or result of OA is still unclear.
Studies with animals have provided convincing
evidence that cartilage is arthritogenic. Arthritis has
been induced by intra-articular injection of allogenic
cartilaginous particles into rabbit stifle joints (Evans
et al., 1984). Also in canine stifle joints, OA,
characterized by joint inflammation, joint stiffness
and osteophyte formation, has been induced after intra-
articular injections of autologous costal cartilage
(Chrisman et al., 1965). Collagen-induced arthritis
(CIA) in rodents inspired researchers to investigate
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Fig. 1. Schematic representation of humoral immune response in dogs with cruciate disease. Step 1: impaired CrCL with release of collagen type I
(CAg), Step 2: collagen uptake by macrophage (Mq), Step 3: antigen presentation to naive T cell (NT), Step 4: B cell (B) activation/differentiation
with antibody production (Ab), Step 5: release of antibodies in synovial tissue and Step 6: release of antibodies in the synovial fluid and formation of
immune complexes with collagen type I.autoimmunity to collagen type II in the pathogenesis of
human RA, since the histopathology and nature of the
immune response is similar in both diseases (Trentham
et al., 1977; Courtenay et al., 1980). In CIA, collagen
serves as a direct stimulus for the local production of
anticollagen type II antibodies in the synovial tissue.
These antibodies engage in the formation of comple-
ment-binding antigen–antibody complexes which are
said to play a major part in the induction and
perpetuation of synovial inflammation. In the SF of
human patients with RA and OA, anticollagen
antibodies (Menzel et al., 1976, 1978; Stuart et al.,
1983; Jasin, 1985) and immune complexes (Cooke,
1980) have been discovered. In RA, these antibodies are
produced locally by plasma cells that are located in the
synovial tissue (Smiley et al., 1968). Also in dogs with
RA and cruciate disease, anticollagen type I and II
antibodies have been detected in both sera and SF, with
a higher incidence in the SF thus indicating a local
antibody production (Niebauer and Menzel, 1982;
Niebauer et al., 1987; Bari et al., 1989). Histological
studies on synovial tissue from stifle joints of dogs with
cruciate disease also support the belief that anticollagen
antibodies are produced locally within the synovial
tissue (Hewicker et al., 1999; Tirgari, 1977; Galloway
and Lester, 1995; Lawrence et al., 1998). The main cell
types detected in the synovial tissue are macrophages,
T-lymphocytes, B-lymphocytes and plasma cellsbelonging predominantly to the IgG isotype (Hewicker
et al., 1999; Tirgari, 1977; Galloway and Lester, 1995;
Lawrence et al., 1998; Lemburg et al., 2004). A
significant higher amount of IgG and IgM has been
detected in the synovial tissue of stifle joints of dogs
with cruciate disease compared to normal stifle joints
(Lawrence et al., 1998). In addition, one study reported
that 67% of the dogs had distinct lymphoplasmacytic
nodules within the synovial tissue (Galloway and
Lester, 1995). However, up to date no synovial tissue
cells from cruciate patients have been cultured to
discover if they effectively produce antibodies. There-
fore, it remains uncertain whether antibodies play an
active role in the initiation of CrCL rupture. Antic-
ollagen type I and II antibodies have also been detected
in the SF of stifle joints with OA secondary to
arthropathies other than CrCL rupture, suggesting that
these antibodies are not specific for the type of joint
disorder (de Rooster et al., 2000). A prospective study in
which anticollagen type I antibodies have been
measured sequentially over a 12–18 months period in
the SF of dogs initially presented with unilateral CrCL
rupture, could not provide evidence that anticollagen
antibodies initiated CrCL damage in dogs, since not all
dogs with high antibodies developed a contralateral
CrCL rupture (de Bruin et al., 2007a). Nevertheless, it is
possible that anticollagen antibodies perpetuate chronic
joint inflammation in some dogs with cruciate
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arthritogenic agent. In predisposed dogs, higher antic-
ollagen type I titers were found in the stifle joints that
eventually sustained a CrCL rupture, compared to the
titers in a remote joint. This finding suggests that there
was an inflammatory process with production of
collagen-specific antibodies, present in these joints
before detectable joint instability occurred (de Bruin
et al., 2007a). Antigens can also maintain joint
inflammation by forming immune complexes with
antibodies. In antigen-induced arthritis in rabbits, large
amounts of the inducing antigen persists for long
periods of time in the form of immune complexes within
the cruciate ligaments (Cooke et al., 1972). In addition,
marked disorganized cellular architecture, loss of fiber
orientation and infiltration of mononuclear and poly-
morphonuclear cells were demonstrated within the
cruciate ligaments of these animals (Goldberg et al.,
1982). Persistence of the antigen is believed to be
responsible for the chronicity of the joint inflammation
and contribute to the degeneration of the cruciate
ligaments resulting in decreased mechanical strength
(Goldberg et al., 1982).
3. Cell-mediated immune response in cruciate
disease
Variable amount of synovitis, with an inflammatory
infiltrate (mainly characterized by B- and T-lympho-
cytes, macrophages and IgG+, IgM+ and IgA+ plasma
cells), is present in the stifle joints of dogs with cruciate
disease (Galloway and Lester, 1995; Lemburg et al.,
2004). The significance of these inflammatory cells is
still poorly understood. It has been suggested that they
are indicative of a cell-mediated immune response
(Galloway and Lester, 1995). Studies in dogs with CrCL
rupture detected many MHC class II antigen positive
cells morphologically resembling dentritic cells in the
synovial tissue of affected stifle joints (Hewicker et al.,
1999; Lemburg et al., 2004). These cells can be
involved in the activation of naive T helper (Th) cells
which will differentiate towards Th1, Th2 and the more
recently discovered Th17 (Jin et al., 2008). It has
become apparent in recent years that the immune
responses driven preferentially by activated Th subsets
are involved in the development of pathological
immune disorders. Although an attempt to dichotomize
complex diseases in terms of just Th1 or Th2 may be an
oversimplification, the concept not only clearly allows
better understanding of the mechanisms involved in the
pathogenesis of the disease but also provide the basis for
the development of novel strategies for treatment.Currently there is convincing evidence that Th1 cells
play a central role in initiating and perpetuating the
chronic joint inflammation in RA and OA (Schultze and
Kalden, 2001; Miltenburg et al., 1992; Bucht et al.,
1996; Kanik et al., 1998; Canete et al., 2000; Davis
et al., 2001). This could lead to massive activation of the
synovial macrophages that are present in the synovial
tissue. In mice with experimentally induced stifle joint
instability, recent immunohistochemical studies dis-
covered many activated (MRP (myeloid related protein)
8 and MRP14 positive) synovial lining macrophages in
the synovial tissue (Blom et al., 2004; van Lent et al.,
2004). In these studies, results strongly suggest that the
synovial lining macrophages are fundamental in
mediating osteophyte formation and, since selectal
removal of the lining macrophages by clodronate-laden
liposomes significantly blocked osteophyte formation
(Blom et al., 2004; van Lent et al., 2004). Th17 cells
have been shown to play a cruciate role in the induction
of autoimmune tissue injuries, inflammation and
infection (Jin et al., 2008).
The question which remains to be answered is what
causes the immune reactions in canine cruciate disease.
In human patients with OA, denatured cartilaginous
detritus have been detected in the lysosomes of
synoviocytes (Saito et al., 2002). Immunohistochemical
staining of these cells showed that they were of the
macrophage lineage (CD68-positive cells) (Saito et al.,
2002). This could mean that the denatured cartilaginous
detritus is recognized as an intra-articular foreign body,
and is phagocytized and processed. It could be
hypothesized that in CrCL rupture, antigen presenting
cells take up and process joint-derived antigens such as
collagen type I and II and present it to naive Th cells.
Currently there is no evidence of follicular lymphoplas-
matic inflammatory change with germinal centra in the
synovium of dogs with spontaneous CrCCL rupture
(Lemburg et al., 2004), which suggests the absence of
local antigen presentation. A number of findings in dogs
with CrCL rupture suggest that joint inflammation is
possibly initiated and perpetuated by the response of Th
cells to antigenic peptides presented by antigen
presenting cells. For instance, immunohistochemical
studies have detected MHC class II- and CD1c -
expressing dendritic cells clustered with lymphocytes,
largely composed of CD4+ T cells, in the synovial tissue
of stifle joints from dogs with cruciate disease
(Lemburg et al., 2004). Flow cytometric analysis of
canine SF cells isolated from normal and cruciate
deficient stifle joints, showed higher percentages of
mainly CD4+ T cells in the affected stifle joints
(Faldyna et al., 2004a,b). Only a slight increase in CD8+
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lymphocytes expressing the CD45RA isoform is
significantly decreased in SF of the affected stifle
joints (Faldyna et al., 2004a,b). CD45RA expression in
humans is restricted to B cells and naive T cells
(Lydyard and Grossi, 1993). This suggests that cells in
the SF of cruciate deficient stifle joints are activated by
an antigen. Up to date the exact distribution of CD45RA
among lymphocytes in dogs has not been examined.
However, the expression of the different CD45 isoforms
show a characteristic pattern of cellular distribution,
which is conserved throughout mammalian revolution
(Thomas, 1989). Moreover, a similar age-related
difference in the distribution of CD45RA positive cells
between dogs and humans is observed (Felsburg, 2002).
These findings suggest a similar distribution of
CD45RA positive cells in dogs and humans. Another
study examining synovial macrophages in the synovial
tissue of dogs with cruciate disease found that the cell
density was associated with the severity of radiographic
OA (Klocke et al., 2005). The higher percentage of
activated CD4+ T cells and synovial macrophages in
cruciate disease are suggestive of a Th1 response. So, it
is possible that collagen type I, released from the
impaired CrCL, is presented to naive Th cells resulting
in a Th1 response with activation of macrophages
(Fig. 2). These macrophages could phagocytize the free
collagen type I antigens and/or the immune complexes
and release proteinases that further damage the
impaired CrCL. In a recent study lymphocyte reactivity
to collagen type I was assessed in dogs with cruciate
disease by culturing peripheral blood mononuclear cells
with human collagen type I, and was compared to sham
operated and normal dogs. This study demonstrated that
lymphocyte reactivity to collagen type I does occur in
dogs with CrCL rupture, however, some of the sham
operated dogs and healthy dogs tested positive as well
(de Bruin et al., 2007b). In addition, PBMC prolifera-
tion to collagen type I was very diverse in dogs that
sustained a CrCL rupture in the contralateral stifle joint,
suggesting that collagen reactive T cells do not play a
primary role in CrCL disease. It is possible, however,
that the reactive T-lymphocytes home to the stifle joints
and initiate a local immune response. Further research is
required to determine whether cellular reactivity to
collagen type I exists locally in the stifle joints and if
they could initiate cruciate degradism.
4. Cytokines and joint inflammation
In human patients with ACL injury and dogs with
CrCL injury, OA continues to develop despite surgicalrestoration of the joint stability. This has lead to the
suggestion that biomechanical stresses together with
biochemical factors are responsible for the OA changes
(Elkins et al., 1991; Cameron et al., 1994, 1997;
Rayward et al., 2004). Biochemical factors that have
received massive attention as possible candidates for
inducing and perpetuating joint inflammation are pro-
inflammatory cytokines (Shinmei et al., 1990; Yuan
et al., 2003; Goldring, 1999). Some cytokines can
worsen disease (pro-inflammatory), whereas others can
reduce inflammation and promote healing (anti-inflam-
matory). Importantly, cytokines can influence the
outcome of an inflammatory response by exerting
effects on various stages of the immune response. There
is compelling evidence that certain cytokines play an
important role in joint inflammation and cartilage
degradation in diseased and/or damaged joints such as
interleukin IL-1, IL-6 and tumor necrosis factor TNF-a
as well as IL-8. Cytokine profiles have been studied in
human patients with ACL injury (Cameron et al., 1994,
1997; Irie et al., 2003) and there seems to be an
imbalance between the pro-inflammatory (TNF- a, IL-
1b, IL-6, IL-8) and anti-inflammatory cytokines (IL-
1ra, IL-10). This imbalance could have the potential to
engender cartilage loss and eventually lead to OA
(Cameron et al., 1994, 1997). There are also immunor-
egulatory mechanisms present in the joint (Brennan
et al., 1995; Bucht et al., 1996). The two major
immunoregulatory factors present in the joint are the
cytokine inhibitors and the growth factors. Immunor-
egulatory factors are up-regulated in humans with
chronic joint inflammation, however, they are appar-
ently insufficient to ablate the inflammation as pro-
inflammatory bioactivity is still detected in the diseased
joints (Brennan et al., 1995). Studies on pro- and anti-
inflammatory cytokines and immunoregulatory
mechanisms in dogs with joint disease are only in
the begin phases (Fernihough et al., 2003). Fig. 3
describes the important pro- and anti-inflammatory
cytokines, cytokine inhibitors and growth factors that
could play a role in canine cruciate disease based on
studies examining human joint pathologies, animal
models of OA or arthritis and studies examining various
arthropathies in dogs.
4.1. Pro-inflammatory cytokines
The cytokines IL-1 and TNF-a are primarily pro-
inflammatory cytokines and, although they are structu-
rally unrelated and bind to different receptors, they
share remarkable similarities in biological activities,
often working synergistically. Both IL-1 and TNF-a are
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Fig. 2. Schematic representation of cellular immune response in dogs with cruciate disease. Step 1: impaired CrCL with release of collagen type I
(CAg), Step 2: collagen uptake by macrophage (Mq), Step 3: antigen presentation to naive T cell (NT), Step 4: macrophage activation (AMq), Step 5:
phagocytosis of free collagen and Step 6: proteolytic degradation of the injured CrCL.
Fig. 3. Schematic representation of the possible cytokine cascade in dogs with CrCL rupture (begin at the antigen presentation in the synovial tissue;
black lines: stimulation; red lines: inhibition, green boxes: pro-inflammatory, red boxes: anti-inflammatory). Antigen stimulated dendritic cells
present antigen to naive T-lymphocytes. Activated CD4+ T-lymphocytes can then stimulate different cells (macrophages, monocytes, B-
lymphocytes, fibroblasts and synoviocytes) by cytokine release to produce antibodies, osteophytes, ligament degeneration and synovial tissue
proliferation (black lines). Next to the pro-inflammatory reactions, anti-inflammatory responses are seen (red lines). Ab: antibodies, Ag: antigen,
AMq: activated macrophage, B: B-lymphocyte, bFGF: basic fibroblast growth factor, C: chondrocyte, CaCL: caudal cruciate ligament, CAg:
collagen antigen, CD4+T: CD4+ T-lymphocyte, DC: dendritic cell, IFN-g: interferon gamma, IGFs: insulin-like growth factors, Il: interleukin, Il-
1Ra: interleukin 1 receptor antagonist, F: fibroblast, Mo: monocyte, NT: naive T-lymphocyte, PC: plasma cell, PDGF: platelet-derived growth
receptor, S: synoviocyte, sIL-1R: soluble IL-1 receptor, sTNF-aR: soluble TNF-a receptor, TGF-b: transforming growth factor beta, and TNF-a:
tumor necrosis factor alpha. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
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Fig. 4. Schematic representation of Il-1 and TNF-a properties in joint pathologies.involved in a number of physiological and pathophy-
siological processes (Fig. 4) and are produced during
inflammation, injury, immunological challenge or
infection (Tracey, 1994). Cells from the monocyte/
macrophage lineage are the principle source of IL-1 and
TNF-a, however, a variety of cells are capable of
secreting them, e.g. B cells, T cells, natural killer cells,
mast cells, neutrophils, basophils, eosinophils, kerati-
nocytes, plasma cells, adipocytes, astrocytes and
synoviocytes (Tracey, 1994; Wood et al., 1985; Sukedai
et al., 2004). IL-1 and TNF-a initiate or suppress gene
expression of several proteins and promote inflamma-
tory cell infiltration by up-regulating leukocyte adhe-
sion molecules on endothelial cells (Hulkower et al.,
1994). They also induce prostaglandin E2 (PGE2)
production that induces vascular permeability and,
therefore, an increased infiltration and activation of
inflammatory cells (Hulkower et al., 1994). IL-1 and
TNF-a are thought to be the main cytokines responsible
for cartilage loss as they stimulate chondrocytes and
synoviocytes to produce various enzymes (Shinmei
et al., 1990). Both cytokines augment the proliferation
of fibroblasts and synovial cells, which results in the
formation of joint fibrosis (Pelletier et al., 1996).
IL-1 and TNF-a are the first cytokines generated by
activated monocytes and macrophages in CIA and
human RA. They stimulate synoviocytes, chondrocytes
and osteoblasts to produce more IL-1 and TNF-a, thus
amplifying the cytokine concentrations and resulting in
severe inflammation (Joosten et al., 1996; Bertazzolo
et al., 1994; Cheon et al., 2002). In humans with primary
OA, IL-1 is also the most abundantly synthesized pro-
inflammatory cytokine by the synovial tissue (Pelletier
et al., 1993a), however, it is hardly detectable in their SF(Bertazzolo et al., 1994; Holt et al., 1992; Kaneyama
et al., 2002). In humans with secondary OA due to ACL
injury, no difference in SF IL-1 levels has been found by
ELISA between the injured knee joints and the healthy
knee joints (Cameron et al., 1994, 1997). Nevertheless,
IL-1 bioactivity is not only influenced by its absolute
amount present in the SF but also by the number of
receptors and specific inhibitors. Increased expression
of IL-1 receptor type I on chondrocytes and synovial
fibroblasts in human OA has been detected (Martel-
Pelletier et al., 1992; Sadouk et al., 1995). In addition,
the percentage of receptor occupancy required to elicit
enzyme stimulation is significantly lower in human OA
cells than in normal cells (Martel-Pelletier et al., 1992).
For example, osteoarthritic chondrocytes only need
approximately 1% receptor occupancy, while normal
chondrocytes require 4% (Martel-Pelletier et al., 1992).
This suggests that even a small amount of bioactive IL-1
present in the SF could perpetuate joint inflammation in
human OA, and perhaps also in ACL injured knee
joints. In dogs with arthropathy, conflicting results are
found for the cytokine IL-1. Dogs with immune-
mediated polyarthritis have high IL-1b gene expression
in isolated SF cells (Hegemann et al., 2005). Yet, SF IL-
1 bioactivity is only found in 8% of the samples (Carter
et al., 1999). In dogs with experimentally transected
CrCL (Pond-Nuki model), bioactivity of IL-1 varied
from undetectable to increased in the operated stifle
joints (Carter et al., 1999; Fernandes et al., 1997).
Significant higher levels were found by bioassay in the
SF of dogs with naturally occurring CrCL rupture
compared with SF of normal dogs (Fujita et al., 2006).
An increase in IL-1 positive cells is also detected in the
synovial tissue and cartilage of the Pond-Nuki dogs
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with arthropathy, small amounts of IL-1 is sufficient for
maintaining joint inflammation, however, more
research is needed on this matter.
It was generally believed that TNF-a is primarily
involved in the acute phase of joint inflammation
(Cameron et al., 1997; Joosten et al., 1996; Bolon et al.,
2004). However, it is now clear that this cytokine also
has a function in chronic joint inflammation (Sukedai
et al., 2004; Emshoff et al., 2000). High levels of TNF-a
are detected by ELISA in the SF of human patients with
chronic RA (Isomaki et al., 1996; Lettesjo et al., 1998;
Petrovic-Rackov and Pejnovic, 2006). In addition,
clinical trials targeting TNF-a (anti-TNF-a antibodies,
soluble TNF-a receptors) ameliorate disease symptoms
in patients with acute and chronic RA (Brennan et al.,
1995; Macias et al., 2005). Also in joints with chronic
ACL injury, TNF-a levels remain elevated (Cameron
et al., 1997; Irie et al., 2003; Marks and Donaldson,
2005). These studies provide evidence that TNF-a
contributes to the pathogenesis of these diseases, even
in the chronic stages. In dogs with RA, spontaneous
CrCL rupture and experimentally transected CrCL,
TNF-a bioactivity in the SF varied from undetectable to
elevated (Carter et al., 1999; Venn et al., 1993; Fujita
et al., 2006; Hay et al., 1997). Recently, TNF-a mRNA
expression has been detected in SF cells from dogs with
immune-mediated arthritides and spontaneous CrCL
rupture, with higher levels in the immune-mediated
group (Hegemann et al., 2005). These studies did not
correlate disease duration in function of TNF-a activity.
It is therefore difficult to conclude which role TNF-a
plays in dogs with arthropathy. Furthermore, Il-1 assays
and the TNFa assays used may have detection limits
which are not as low as the levels at which these
cytokines function biologically, so that the inability to
demonstrate their activity in the synovial fluids does not
exclude the possibility that the cytokines are present at
functional levels (Carter et al., 1999). Another
important inflammatory cytokine is IL-6, a multi-
functional cytokine that can be produced by most, if not
all, cell types, especially upon stimulation with IL-1 and
TNF-a (Shinmei et al., 1990; Hirano, 1994). It regulates
immune responses, haemopoiesis and is the most
important inducer of the hepatic acute-phase response
(Hirano, 1994). Although IL-6 does not exhibit any of
the pro-inflammatory properties of IL-1 and TNF-a, it is
a potent B cell growth and differentiation factor
(Hirano, 1994). Therefore, it can indirectly exacerbate
inflammation through augmentation of antibodies
against collagen or other joint antigens. Intriguingly,
although IL-6 is considered an inflammatory cytokine,it also possesses anti-inflammatory properties. IL-6
inhibits proteolytic enzyme production by IL-1 and
TNF-a stimulated chondrocytes, thereby decreasing
cartilage destruction (Shinmei et al., 1990, 1991). In
human patients with various inflammatory arthritides,
high levels of IL-6 is detected in the SF by ELISA, as
well as in the SF from human patients with primary OA
and ACL injury (Cameron et al., 1994, 1997; Irie et al.,
2003; Raza et al., 2005). The levels detected by
bioassay, are positively correlated with both the clinical
and laboratory parameters of inflammation in the same
joint (Miltenburg et al., 1991). These studies implicate
that IL-6 is a possible marker of joint inflammation in
general, but not of a specific joint pathology. Cytokine
studies of dogs with various arthropathies also implicate
IL-6 as a general indicator of joint inflammation. Dogs
with natural occurring and experimentally induced
CrCL rupture have higher IL-6 bioactivity in their SF
compared with healthy dogs (Carter et al., 1999; Venn
et al., 1993; Fujita et al., 2006; Hay et al., 1997), SF of
dogs with CRA have significant higher IL-6 bioactivity
than dogs with natural occurring CrCL rupture (Carter
et al., 1999). Higher IL-6 gene expression is also
detected in SF cells from dogs with immune-mediated
polyarthritis compared with that from dogs with natural
occurring CrCL rupture (Hegemann et al., 2005).
Higher levels of IL-6 found in inflammatory arthritides
is in accordance with the higher amount of joint
inflammation seen in these joints. The presence of
higher amounts of IL-6 in the synovial fluid of OA and
RA joints in comparison with IL-1 and TNF-a may
possibly be due to induction during the disease process,
possibly by transient peaks of IL-1 and TNF activity,
and enhanced by binding with soluble IL-6 receptors
(Carter et al., 1999).
The involvement of chemokines in joint inflamma-
tion and cartilage degradation has recently been
revealed (Peichl et al., 1992; Borzi et al., 1999;
Kirkham et al., 1999; Lisignoli et al., 1999). Chemo-
kines selectively enhance the migration and activation
of particular subpopulations of leukocytes (Male,
1993). Studies of chemokine expression have provided
strong evidence for their involvement in the pathogen-
esis of human RA and OA, especially for the chemokine
IL-8 (Endo et al., 1991; Furuzawa and Alocer, 1999;
Kaneko et al., 2000). IL-8 is one of the most potent
chemo-attracting factors for neutrophils and T cells,
both in vitro and in vivo (Endo et al., 1991; Larsen et al.,
1989; Akahoshi et al., 1994). In the presence of IL-1,
TNF-a and lipopolysaccharide, IL-8 is produced by a
variety of cells, including leukocytes, fibroblasts,
endothelial cells, chondrocytes, and synoviocytes
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Hirota et al., 1992; Deleuran et al., 1994a; Van Damme,
1994; Ogura et al., 2005). Besides attracting poly-
morphonuclear cells, IL-8 also induces expression of
adhesion molecules, neutrophil degranulation and
production of oxygen metabolites (Baggiolini et al.,
1994), thereby able to cause tissue damage. IL-8 has
been detected in high levels by bioassay in the SF of
human patients with RA and in a lower concentration in
the SF of human patients with primary OA (Furuzawa
and Alocer, 1999; Symons et al., 1992). High levels of
IL-8 have also been detected by ELISA in the SF of
ACL injured knee joints (Cameron et al., 1994, 1997;
Irie et al., 2003). Up to date, only the gene expression of
IL-8 has been examined in dogs with different
arthropathies. Higher expression was detected in
inflammatory arthritides compared with the expression
in cruciate disease according to Hegemann et al. (2005),
whereas no significant difference in gene expression has
been detected in canine OA differing in etiopathogen-
esis (de Bruin et al., 2005). In a more recent study in
dogs presented with unilateral CrCL rupture, IL-8
expression was found in the affected stifle joint and not
in the contralateral stifle joint at time of admission.
However, at rechecks, the IL-8 expression tended to be
higher in the non-operated contralateral stifle joints that
will rupture their CrCL during the next 6 months than in
those that will not. This finding suggests the presence of
an inflammatory process in these joints before CrCL
rupture becomes clinical apparent (de Bruin et al.,
2007c).
Another important cytokine is interferon (IFN)-g.
IFN-g can be considered inflammatory because it
augments TNF-a activity and induces nitric oxide
(Sebbag et al., 1997). It also stimulates naive Th cells to
evolve into Th1 cells, thereby favoring cellular
immunity. Intriguingly, IFN-g also has anti-inflamma-
tory activities since it possesses antiviral activity,
activates T cells to become cytotoxic T cells and inhibits
IL-1, IL-8 and metalloproteinase production by
synoviocytes (Ghezzi and Dinarello, 1988; Seitz
et al., 1994). Data concerning the role of IFN-g in
septic antigen-induced arthritis are conflicting. IFN-g
displays inflammatory properties when administered
intravenously in the initiation phase whereas it
ameliorates joint inflammation when administered later
in the disease process (Puliti et al., 2000). In human RA,
clinical trials with IFN-g only showed partial and
temporal benefit (Cannon et al., 1989; Cannon et al.,
1993) or no significant improvement (Veys et al., 1997).
The presence and possible role of IFN-g in canine
cruciate disease has not been extensively studied. Itsgene expression appears to be slightly higher in SF cells
of stifle joints from CrCL rupture than from immune-
mediated arthritis (Hegemann et al., 2005).
4.2. Immunoregulatory mechanisms
4.2.1. Cytokine inhibitors
Cytokine inhibitors are of considerable therapeutic
interest for ameliorating chronic inflammatory diseases.
Two main categories of cytokine inhibitors exist: the
receptor antagonist and the soluble cytokine receptors.
One specific receptor antagonist has been studied
extensively, namely the interleukin-1 receptor antago-
nist (IL-1Ra). IL-1Ra shares a high degree of homology
with IL-1 and is capable of binding to the IL-1 receptors
on cell surfaces without transducing a signal (Arend
et al., 1990; Arend, 1993), thereby inhibiting IL-1. It is
produced by several cell types, including monocytes,
synoviocytes and chondrocytes (Arend et al., 1990;
Caron et al., 1996). A 100-fold excess of IL-1Ra must
be present in order to effectively block the effects of IL-
1 since target cells exhibit full biological response even
when only a small percentage of the IL-1 receptors on
each cell are occupied (Arend et al., 1990). In human
patients with RA and OA, a relative deficit in the
production of IL-1Ra has been detected in the synovial
tissue (Firestein et al., 1994; Fujikawa et al., 1995).
Also in the SF of human patients with chronic ACL
injury, significant less IL-1Ra levels was detected
(Cameron et al., 1994, 1997; Irie et al., 2003; Marks and
Donaldson, 2005). Thus, without sufficient neutralizing
levels of IL-1Ra, even low levels of IL-1 are sufficient
for maintaining joint inflammation. Up to date, the
presence and possible role of IL-1Ra in canine cruciate
disease has not been examined. However, since in
human medicine the administration of IL-1RA into the
joint space has been suggested to influence the clinical
course of painful and debilitating forms of arthritis
(Arend, 1993), it would be worthwhile to do this.
Soluble truncated versions of membrane cytokine
receptors have been isolated in normal and abnormal
biological fluids from humans and mice (Fernandez,
1991). These soluble cytokine receptors are involved in
the regulation of cytokine activity (Fernandez, 1991).
They act as competitive inhibitors with the membrane
cytokine receptors for the binding of cytokines, thereby
inhibiting subsequent signal transduction (Fernandez,
1991). They bind to IL-1 but not to IL-1Ra (Symons
et al., 1991). Many soluble cytokine receptors have been
identified to date (Fernandez, 1991), however, the most
investigated in regard to arthritis are those for IL-1 and
TNF-a. Soluble IL-1 type II receptors have been
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(Kaneyama et al., 2005). Soluble TNF receptors are
increased in the sera and SF of patients with RA (Cope
et al., 1992). Antagonism of TNF-a bioactivity via the
use of soluble TNF receptors has resulted in beneficial
effects in preclinical animal studies. Patients with active
RA, polyarticular juvenile chronic arthritis, psoriatic
arthritis and ankylosing spondylitis are successfully
treated with a recombinant human TNF-a receptor
fusion protein (Cole and Rabasseda, 2004). To the
authors’ knowledge, soluble cytokine receptors have
not been investigated in canine cruciate disease.
Knowing that CrCL rupture in dogs has a moderate
to severe inflammatory component, it would be
worthwhile to investigate the presence, role and
possible therapeutic use of these inhibitors in cruciate
disease, in the hope to prevent rupture in the future.
4.2.2. Growth factors
Growth factors are proteins that enhance wound
healing in damaged tissues. An immunohistochemical
study in rabbits investigated the expression of growth
factors in experimentally injured medial collateral
ligaments and CrCL (Lee et al., 1998). Transforming
growth factor (TGF)-b, platelet-derived growth factor
(PDGF) and basic fibroblast growth factor (bFGF) were
detected in vivo in the ligaments in the early healing
stage (Lee et al., 1998). There were differences in
staining between the CrCL en the medial collateral
ligament, namely, the CrCL showed limited staining
that was restricted to the edges of the lesion, whereas
intensive staining of the total lesion was seen in the
medial collateral ligament (Lee et al., 1998). This
suggests that there could be a shortage of growth factors
in the injured CrCL and could be a possible explanation
why injured cruciate ligaments heal poorly.
TGF-b is chemotactic for fibroblasts and stimulates
the synthesis of collagen and non-collagenous protein in
fibroblasts of CrCL and medial collateral ligament
(Postlethwaite et al., 1987; Marui et al., 1997). TGF-b
suppresses the production of a wide diversity of
proteolytic enzymes including the metalloproteinases
(MMP), and stimulates the synthesis of their respective
inhibitor (Kerr et al., 1990; Overall et al., 1989; Uria
et al., 1998). Intra-articular administration of TGF-b in
experimentally overstretched CrCL injury in rabbits
significantly enhanced the stiffness of the injured CrCL
(Kondo et al., 2005). However, it did not restore the
elongated CrCL back to its normal length. In a bone-
patellar tendon-bone graft CrCL reconstruction in dogs,
intra-articular administration of TGF-b, together with
epidermal growth factor, improved the structuralproperties of the autograft (Yasuda et al., 2004). These
studies suggest that application of TGF-b has a positive
effect on the collagen network in the injured CrCL and
might have therapeutic use in an overstretched CrCL
injury in dogs. However, the use of TGF-b as a possible
therapeutic agent must be studied more extensively
since TGF-b is also capable of promoting inflammation
(Wahl et al., 1989). TGF-b1 stimulates the gene
expression of pro-inflammatory cytokines in synovial
fibroblasts from human patients with RA and OA
(Cheon et al., 2002). In an animal model of RA, intra-
articular administration of TGF-b induced an arthritis
characterized by synovial hyperplasia and infiltration of
leukocytes (Wahl et al., 1993). Intra-articular anti-TGF-
b antibody treatment of these animals blocked not only
the inflammatory cell accumulation but also the tissue
pathology (Wahl et al., 1993). TGF-b also stimulates
the formation of osteophytes in mice with experimen-
tally induced CrCL instability (Blom et al., 2004).
Insulin-like growth factors (IGF)-I and -II could
possibly be used therapeutically in arthritis since they
can reduce cartilage and ligament degradation by
stimulating proteoglycan and collagen synthesis, even
in the presence of IL-1 and TNF-a (Tyler, 1989;
Hardingham et al., 1992). IGFs in vivo are predomi-
nantly bound to one of the six defined IGF-binding
proteins (IGFBP) (Kelley et al., 1996; Baxter, 2000).
IGFBPs are not simply passive carriers for the IGFs but
have particular properties specific for each binding
protein (Kelley et al., 1996; Baxter, 2000). Through
different tissue expression and specific proteolysis of
these binding proteins, IGFBP are able to stimulate and/
or inhibit the action of IGFs (Baxter, 2000). Thus,
IGFBP can regulate the precise mechanism of action of
IGF-I and -II (Kelley et al., 1996; Baxter, 2000; Jones
and Clemmons, 1995). In human patients with RA and
OA, a considerable increase in levels of IGF-I and -II
are found in the SF compared with normal patients
(Fernihough et al., 1996; Whellams et al., 2000). Levels
of IGFBP-3 are also greatly enhanced together with a
decrease in protease activity against this binding
protein. Thus, a molar excess of IGFBP-3 to IGF
exists whereas the opposite is found in normal SF
(Whellams et al., 2000). This implies that, despite
having an increased level of IGF-I and -II, the growth
factors are predominantly bound to high-affinity
binding proteins and are unable to bind to their
receptors. In the SF of canine stifle joints with CrCL
rupture, increased levels of IGF-I and -II are found after
surgery. The concentration declined after 5 months but
remained elevated compared with the contralateral stifle
joints (Fernihough et al., 2003). These cruciate deficient
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(Fernihough et al., 2003). Thus, even though the IGF
system is elevated in canine CrCL rupture, its tissue
availability may be limited due to alterations in IGFBP
profiles.
4.2.3. Anti-inflammatory cytokines
Anti-inflammatory cytokines decrease the produc-
tion and/or activities of inflammatory cytokines in vivo
and in vitro (Goldring, 1999). Two important anti-
inflammatory cytokines are IL-4 and IL-10. Interleukin-
4 is a multifunctional cytokine that, in the joint, is only
secreted by Th cells (Banchereau and Rybak, 1994;
Sugiyama et al., 1995). It inhibits the production
(spontaneous and induced) of IL-1, IL-6, IL-8, TNF-a
and PGE2 by monocytes and synovial cell cultures
isolated from human patients with RA (Seitz et al.,
1994; Banchereau and Rybak, 1994; Sugiyama et al.,
1995). IL-4 can enhance the antigen-presenting
capacity of B cells towards CD4+ T cells, thereby
favoring T and B cell interactions (Banchereau and
Rybak, 1994). This leads to enhanced production of
IgM, IgG and large amounts of IgE (Banchereau and
Rybak, 1994). This property of IL-4 could be
considered inflammatory, however, the overall effect
of IL-4 in an inflammatory tissue will depend on the
target cells, the differentiation status and the influence
of other cytokines in the environment (Banchereau and
Rybak, 1994).
Interleukin-10 is a natural suppressant of a number of
inflammatory responses. It inhibits MHC class II
expression on antigen presenting cells, T cell prolifera-
tion, production of IL-1b and TNF-a in activated
synovial tissue cultures (Isomaki et al., 1996; Katsikis
et al., 1994) and of IL-8 in SF and synovial tissue cell
cultures (Deleuran et al., 1994b; Sugiyama et al., 1995).
Furthermore, IL-10 up-regulates IL-1Ra expression in
monocyte cultures (Katsikis et al., 1994). It also
modulates TNF-a production by inducing the synthesis
of the soluble TNF receptors whilst down-regulating the
surface expression of the cytokine receptor (Brennan
et al., 1995; Katsikis et al., 1994). IL-10 suppresses the
release of reactive oxygen intermediates and nitric
oxide in macrophages, thereby limiting tissue damage
(Bogdan et al., 1991; Cenci et al., 1993). Interleukin-10
also has the capacity to promote antibody production
(Mosmann, 1994), and it could contribute to the
maintenance of local antibody production in RA
synovial tissues (Lettesjo et al., 1998). Elevated levels
of IL-10 and mRNA expression are detected in the SF
and in the synovial tissue of human patients with RA
and OA (Bucht et al., 1996; Isomaki et al., 1996;Katsikis et al., 1994; Cush et al., 1995). Yet the levels of
IL-10 are inadequate to reduce the inflammation and
limit joint destruction (Isomaki et al., 1996). Also in
dogs with CrCL rupture, gene expression of IL-10 is up-
regulated (Hegemann et al., 2005; de Bruin et al.,
2007c), which might suggest that the immune system in
cruciate disease in dogs is attempting to atone for the
effects of the abundantly expressed pro-inflammatory
cytokines.
4.3. Cytokines involved in Th1 and Th2
differentiation
As stated previously, cellular and humoral immune
responses are orchestrated by subsets of Th cells via
their cytokines. IFN-g, IL-2 and IL-12 are the key
molecules for initiating cell-mediated immune
responses, while IL-4 and IL-10 initiate humoral
immunity (Rook, 1993). Th1 cytokines inhibit the
differentiation of Th2 subsets and vice versa (Rook,
1993).
In human RA, current paradigms suggest that the
cytokine balance is skewed in favor of a cellular
immune response (Th1-type) (Kanik et al., 1998;
Katsikis et al., 1994; Park et al., 2001; Firestein,
2003). Synovial T cells isolated from patients with RA
produce IFN-g and IL-12 after in vitro stimulation
(Morita et al., 1998). In addition, gene expression of
IFN-g is detected in SF cells of human patients with
RA, but not that of IL-4 (Bucht et al., 1996). Recent
research in canine CrCL rupture, showed conflicting
results. Hegemann et al. (2005) found higher expression
of Th1 cytokines (IL-2 and IFN-g) and an almost non-
existent IL-4 expression in the SF cells, possibly
implicating a dominance of cellular immunity. In
contrast, research by de Bruin et al. (2007c) revealed a
low prevalence of IFN- g expression and a relatively
moderate expression of IL-10 which the authors found
to be suggestive for a Th2 dominance in joints with
cruciate disease, favoring a humoral immune response
(de Bruin et al., 2007c).
5. Proteolytic tissue degradation
Dogs with CrCL rupture typically have increased
levels of glycoaminoglycans in their SF, indicating
increased degradation of joint tissue (Arican et al.,
1994). Moreover, the joint tissues of cruciate patients
(synovial tissue, cartilage and CrCL) express many
degradative enzymes including MMPs, cathepsins and
tartrate-resistant acid phosphatase (TRAP) (Spreng
et al., 1999; Muir et al., 2002; Muir et al., 2005a).
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remodeling. MMPs are a family of zinc-dependent
endopeptidases that have the combined ability to
degrade all components of the extracellular matrix
(Brinckerhoff, 1991). Based on their domain structure
and substrate-specificities, MMPs can be divided into
subclasses (collagenases, gelatinases, stromelysins and
membrane type MMP). Collagenases and stromelysin
play an important role in the MMP cascade. Collage-
nases are capable of degrading native collagens. For
example, collagenase-1 (MMP-1) preferentially cleaves
collagen type III, collagenase-2 (MMP-8) has a higher
specificity for collagen type I, and collagenase-3
(MMP-13) for collagen type II (Martel-Pelletier
et al., 2001). Stromelysin (MMP-3) has a broader
substrate-specificity that includes proteoglycans, elas-
tin, laminin, fibronectin, but also collagen type IV, V,
VII, IX, XI and denatured collagen type I (Martel-
Pelletier et al., 2001). Inactivation of the MMPs
involves specific inhibitors, called the tissue inhibitor
of metalloproteinases (TIMP-1, TIMP-2, TIMP-3 and
TIMP-4) that are abundantly present in all body fluids.
Dysregulation of the MMPs, their inhibitors, or both,
can be a key event in shifting the MMP cascade from
physiologic to pathologic conditions (Martel-Pelletier
et al., 2001). There is accumulating evidence that
MMPs play a prominent role in degradation of tendons,
ligaments and articular cartilage in various arthropa-
thies (Pelletier et al., 1993b; Muir et al., 2005a; Martel-
Pelletier et al., 2001; Dalton et al., 1995). In various
joint diseases, an imbalance between MMPs and their
inhibitors exists, in favor of the MMPs. So once
activated, MMPs cannot be sufficiently counteracted
(Lohmander et al., 1993, 1994; Tchetverikov et al.,
2005).
In a CrCL transection model in rabbits, rapid loss of
collagen matrix was associated with a significant
increase in collagenase activity (Amiel et al., 1989).
Moreover, synovectomy of the synovial sheath around
the CrCL in rabbits (thereby exposing the CrCL to the
intra-articular environment), caused an increase in
collagenase activity in the ligament (Amiel et al., 1990).
An experimentally induced partial CrCL injury in
sheep, through transection of the caudolateral band of
the CrCL, caused a significant increase in MMP-13
mRNA levels in the uninjured craniomedial band of this
ligament 6 weeks following injury (Lo et al., 2003).
Importantly, no increase of this collagenase was seen in
the CaCL, suggesting that the observed changes were
ligament specific (Lo et al., 2003). Increases of these
enzymes are suggestive of matrix remodeling and
possibly of degradation of the CrCL. An in vitro studyexamining the effect of mechanical stretch injury to
human ligament cells on the gelatinase (MMP-2)
production and activity demonstrated that more pro-
MMP-2 was produced in ACL fibroblasts compared
with medial collateral ligament fibroblasts (Zhou et al.,
2005). In addition, more pro-MMP-2 was converted into
active MMP-2 in injured ACL fibroblasts compared
with medial collateral ligament fibroblasts (Zhou et al.,
2005). The ACL fibroblasts also maintained a higher
level of active MMP-2 after injury. In fact, injured ACL
fibroblasts released almost 20 times more active MMP-
2 than injured medial collateral ligament fibroblasts
(Zhou et al., 2005). Taken together, these studies
suggest that after injury, the CrCL accumulates very
high levels of pro-MMPs and activeMMPs which could
result in ligament degradation and absorption. This
might explain whymany stretch or partial CrCL injuries
eventually evolve into complete CrCL ruptures in both
humans and animals.
Matrix metalloproteinase levels have been studied in
the SF of human patients with ACL injury. Increased
levels of pro-MMP-1, pro-MMP-3 and TIMP-1 were
found by ELISA in the SF within hours after ACL injury
(Lohmander et al., 1993, 1994; Tchetverikov et al.,
2005). Two weeks after injury, a significant increase of
active MMP-1 and decrease in TIMP-1 was noticed
(Tchetverikov et al., 2005). This could mean that the
amount of inhibitor present in the injured joint is
insufficient to inhibit the activated MMP-1 (Lohmander
et al., 1993, 1994; Tchetverikov et al., 2005). The levels
of pro-MMP-3 reached a maximum several weeks after
injury whereafter it declined. The level did remain
elevated for several years, compared with levels in
uninjured knee joints (Lohmander et al., 1993, 1994).
The level of active MMP-3, however, was not increased
compared with healthy joints, for at least 4 years after
injury (Tchetverikov et al., 2005). These studies show
that proteolytic activity remains high after ACL injury.
Stromelysin activity has also been studied in the SF,
cartilage, synovial tissue and remnants of CrCL of dogs
with CrCL rupture (Fujita et al., 2006; Spreng et al.,
1999). Cartilage explants from CrCL deficient stifle
joints produced more stromelysin than cartilage from
normal stifle joints (Spreng et al., 1999). In addition,
explants of the remnants of ruptured CrCL showed a
tendency to produce higher levels of stromelysin than
normal CrCLs. Higher MMP-3 was detected in the SF
of dogs with CrCL rupture compared with normal stifle
joints (Fujita et al., 2006). Synovial tissue explants from
cruciate deficient stifles, however, produced less
stromelysin than normal synovial tissue (Spreng
et al., 1999). This suggests that stromelysin is produced
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Recently, mRNA expression of MMP was examined in
CrCL cells and SF cells from cruciate deficient dogs and
dogs with intact CrCLs (Muir et al., 2005a). No MMP
expression was found in the CrCL and SF cells of
normal young small breed dogs. The expression of
stromelysin was significantly increased in intact CrCL
cells of older and larger breed dogs compared with
intact CrCL cells from young, small breed dogs. MMP-
1 expression was also found in some of the CrCL cells
from these two groups. Expression of MMP-1 and
MMP-2 was significantly increased in the SF cells of
these large breed dogs compared to the small breed
dogs. Expression of MMP in CrCL and SF cells of these
older, large breed dogs suggests that there is a higher
matrix turnover and/or, possibly, a degenerative process
in the cruciate ligaments. These results relate to the
histopathological findings of Vasseur et al. (1985), who
found degenerative changes in the intact CrCL earlier in
larger breed dogs than in small breed dogs. In dogs with
cruciate disease, gene expression of MMP-1, -2, -3, -9
and -13 was detected in both the CrCL and SF cells, in
particular the gelatinases (MMP-2 and -9) (Muir et al.,
2005a). Significant higher levels of MMP-2 and -9 have
also been detected in the SF of dogs with cruciate
disease (Coughlan et al., 1998; Volk et al., 2003).
Recently, the presence of MMP-1 and TIMP-2 in the SF
of dogs with CrCL rupture and dogs with intact CrCL
has been investigated (Salinardi et al., 2006). This study
found elevated levels of MMP-1 and reduced levels of
TIMP-2 in the SF of cruciate deficient dogs (Salinardi
et al., 2006); MMP-1 levels were decreased in the sera
of dogs with cruciate disease (Salinardi et al., 2006).
This implies that MMP-1 is either expressed at a lower
level systemically and at a higher level within the joint,
or that it leaves the systemic circulation and enters the
damaged joints in dogs with CRCL rupture. The reason
for this is unknown (Salinardi et al., 2006).
The synovial tissue of dogs with cruciate disease also
express other collagenolytic enzymes, for instance
cathepsins and TRAP (Muir et al., 2002, 2005a,b).
Cathepsins are cysteine proteinases that are able to
cleave the N-terminal end of the collagen triple helix,
creating access for other proteolytic enzymes (Kafienah
et al., 1998). TRAP are a class of metalloenzymes that
catalyze the hydrolysis of various phosphate esters and
anhydrides under acidic reaction conditions (Oddie
et al., 2000). TRAP positive cells, such as the synovial
macrophage-like cells, can secrete various proteinases
and generate reactive oxygen species, thus able to
cleave the triple helix of collagen (Halleen et al., 1999;
Tsuboi et al., 2003). Both cathepsin and TRAP areproducts of activated macrophages and synovial
fibroblasts (Hou et al., 2001). In dogs with CrCL
rupture, localization of cathepsin K and TRAP in CrCL
cells correlated with cruciate ligament injury (Muir
et al., 2002). However, studying the gene expression of
these collagenolytic enzymes in SF and CrCL cells,
revealed that only TRAP and cathepsin S were present
in dogs with cruciate disease compared with normal
joints (Muir et al., 2005a). In contrast, cathepsin K
mRNA expression was found in intact CrCL and their
corresponding SF cells, and in cells isolated from
cruciate deficient stifle joints (Muir et al., 2005a), which
would indicate that cathepsin K is important in normal
daily matrix turnover. A limiting factor in these three
studies is that they only examined stifle joints with
cruciate disease and no other joint pathology. It is
therefore risky to conclude that these enzymes correlate
with cruciate injury since they may correlate with
inflammatory changes in general. A very recent study
compared the presence of TRAP and cathepsin K in
ruptured and intact human ACLwith ruptured and intact
canine CrCL (Barrett et al., 2005). Interestingly, a
significant higher amount of TRAP and cathepsin K
positive cells were found in the injured canine CrCL
than in the damaged human ACL, suggesting a different
proteolytic pathology in canine CrCL (Barrett et al.,
2005).
Production of MMPs, cathepsins and TRAP at sites
of inflammation potentially contributes to matrix
degradation. More importantly, it remains to be
determined whether changes in these proteolytic
enzymes initiate cruciate disease in dogs or whether
they are the result of the disease progression.
6. Conclusions
Many veterinarians have endeavored to unravel the
multifactorial ethiopathogeneis of spontaneous CrCL
rupture in dogs, but data are incomplete and the
mechanisms that are responsible for the degenerative
changes in the CrCL remain unclear. One of the major
limitations in most investigations is that most studies in
CrCL disease have focused on the affected stifle joint
after rupture, the end stage of the disease.
Immune-mediated mechanisms could play a role in
the induction of joint inflammation. Indeed, the cruciate
ligaments can act as self-antigens in cases of damage
due to their extra-synovial position and therefore
seclusion from immune surveillance (Osborne et al.,
1995; Kobayashi et al., 2006). The prevalence and
relevance of humoral and cellular reactivity to collagen
type I in dogs with cruciate disease is not yet clear.
M. Doom et al. / Veterinary Immunology and Immunopathology 125 (2008) 143–161156The exact role of pro-inflammatory cytokines, anti-
inflammatory cytokines, chemokines, growth factors
and degradative enzymes in he initiation of cruciate
disease in dogs remains unclear. Determining the initial
inflammatory process, however, could implicate that by
targeting this process, one might be able to prevent
CrCL impairment in the contralateral stifle joint in the
future.
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